These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

823 related articles for article (PubMed ID: 7782761)

  • 1. Repeated exposure of rhesus macaques to low doses of simian immunodeficiency virus (SIV) did not protect them against the consequences of a high-dose SIV challenge.
    Dittmer U; Stahl-Hennig C; Coulibaly C; Nisslein T; Lüke W; Fuchs D; Bodemer W; Petry H; Hunsmann G
    J Gen Virol; 1995 Jun; 76 ( Pt 6)():1307-15. PubMed ID: 7782761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential significance of the cellular immune response against the macaque strain of simian immunodeficiency virus (SIVMAC) in immunized and infected rhesus macaques.
    Voss G; Nick S; Stahl-Hennig C; Coulibaly C; Petry H; Lüke W; Hunsmann G
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2273-81. PubMed ID: 1357081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivation of human immunodeficiency virus type 2 in macaques after simian immunodeficiency virus SIVmac superinfection.
    Petry H; Dittmer U; Stahl-Hennig C; Coulibaly C; Makoschey B; Fuchs D; Wachter H; Tolle T; Morys-Wortmann C; Kaup FJ
    J Virol; 1995 Mar; 69(3):1564-74. PubMed ID: 7853490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus.
    Stahl-Hennig C; Voss G; Dittmer U; Coulibaly C; Petry H; Makoschey B; Cranage MP; Aubertin AM; Lüke W; Hunsmann G
    AIDS; 1993 Jun; 7(6):787-95. PubMed ID: 8363756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants.
    Rud EW; Cranage M; Yon J; Quirk J; Ogilvie L; Cook N; Webster S; Dennis M; Clarke BE
    J Gen Virol; 1994 Mar; 75 ( Pt 3)():529-43. PubMed ID: 8126450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic T lymphocyte response against multiple simian immunodeficiency virusA (SIV) proteins in SIV-infected macaques.
    Venet A; Bourgault I; Aubertin AM; Kiény MP; Levy JP
    J Immunol; 1992 May; 148(9):2899-908. PubMed ID: 1349322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycobacterium bovis bacille Calmette-Guérin enhances pathogenicity of simian immunodeficiency virus infection and accelerates progression to AIDS in macaques: a role of persistent T cell activation in AIDS pathogenesis.
    Zhou D; Shen Y; Chalifoux L; Lee-Parritz D; Simon M; Sehgal PK; Zheng L; Halloran M; Chen ZW
    J Immunol; 1999 Feb; 162(4):2204-16. PubMed ID: 9973496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus.
    Dittmer U; Nisslein T; Bodemer W; Petry H; Sauermann U; Stahl-Hennig C; Hunsmann G
    Virology; 1995 Oct; 212(2):392-7. PubMed ID: 7571408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of antigenic variants of simian immunodeficiency virus (SIVmac) in a seronegative macaque after SIVmac239 infection.
    Chuang LF; Blackbourn DJ; Chuang AJ; Killam KF; Liu X; Li Y; Kung HF; Chuang RY
    Cell Mol Biol Res; 1994; 40(7-8):661-9. PubMed ID: 7787884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-mediated immune response of macaques immunized with low doses of simian immunodeficiency virus (SIV).
    Dittmer U; Spring M; Petry H; Nisslein T; Rieckmann P; Lüke W; Stahl-Hennig C; Hunsmann G; Bodemer W
    J Biotechnol; 1996 Jan; 44(1-3):105-10. PubMed ID: 8717393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV.
    Marthas ML; Sutjipto S; Higgins J; Lohman B; Torten J; Luciw PA; Marx PA; Pedersen NC
    J Virol; 1990 Aug; 64(8):3694-700. PubMed ID: 2164591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occult systemic infection and persistent simian immunodeficiency virus (SIV)-specific CD4(+)-T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV.
    McChesney MB; Collins JR; Lu D; Lu X; Torten J; Ashley RL; Cloyd MW; Miller CJ
    J Virol; 1998 Dec; 72(12):10029-35. PubMed ID: 9811741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques.
    Ansari AA; Mayne AE; Sundstrom JB; Bostik P; Grimm B; Altman JD; Villinger F
    J Virol; 2002 Feb; 76(4):1731-43. PubMed ID: 11799168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo administration of CD4-specific monoclonal antibody: effect on provirus load in rhesus monkeys chronically infected with the simian immunodeficiency virus of macaques.
    Reimann KA; Cate RL; Wu Y; Palmer L; Olson D; Waite BC; Letvin NL; Burkly LC
    AIDS Res Hum Retroviruses; 1995 Apr; 11(4):517-25. PubMed ID: 7632466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow monocyte/macrophages are an early cellular target of pathogenic and nonpathogenic isolates of simian immunodeficiency virus (SIVmac) in rhesus macaques.
    Mandell CP; Jain NC; Miller CJ; Dandekar S
    Lab Invest; 1995 Mar; 72(3):323-33. PubMed ID: 7898051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective induction of protective MHC class I-restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa.
    Murphey-Corb M; Wilson LA; Trichel AM; Roberts DE; Xu K; Ohkawa S; Woodson B; Bohm R; Blanchard J
    J Immunol; 1999 Jan; 162(1):540-9. PubMed ID: 9886431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope.
    Quesada-Rolander M; Mäkitalo B; Thorstensson R; Zhang YJ; Castaños-Velez E; Biberfeld G; Putkonen P
    AIDS Res Hum Retroviruses; 1996 Jul; 12(11):993-9. PubMed ID: 8827215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H.
    Chan WL; Rodgers A; Grief C; Almond N; Ellis S; Flanagan B; Silvera P; Bootman J; Stott J; Kent K
    AIDS; 1995 Mar; 9(3):223-8. PubMed ID: 7755909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.
    Suh YS; Park KS; Sauermann U; Franz M; Norley S; Wilfingseder D; Stoiber H; Fagrouch Z; Heeney J; Hunsmann G; Stahl-Hennig C; Sung YC
    Vaccine; 2006 Mar; 24(11):1811-20. PubMed ID: 16274888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infected macaques that controlled replication of SIVmac or nonpathogenic SHIV developed sterilizing resistance against pathogenic SHIV(KU-1).
    Stephens EB; Joag SV; Atkinson B; Sahni M; Li Z; Foresman L; Adany I; Narayan O
    Virology; 1997 Aug; 234(2):328-39. PubMed ID: 9268165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.